ERIN COLE: Open Payments
NPI 1255033411 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 29 payments from 12 companies in 2025. Trend: 2023 $162 · 2024 $812 · 2025 $639
Food & beverage: $639
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $149 |
| Janssen Pharmaceuticals, Inc | 3 | $85 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $54 |
| ABBVIE INC. | 3 | $53 |
| Braeburn Inc. | 3 | $47 |
| Alkermes, Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Neurocrine BioSciences, Inc. | 1 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
Products named: CAPLYTA, INVEGA, Auvelity, COBENFY, VRAYLAR, BRIXADI, INGREZZA, REXULTI.
Industry payments across LA — which companies pay providers there.
